4880.T
CellSource Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 341.00
−0.58%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.7B | 3.7B | 4.4B | 4.5B | 4.3B |
| Cost of Revenue | 350.7M | 1.6B | 1.9B | 1.3B | 1.2B |
| Gross Profit | 509.3M | 2.1B | 2.4B | 3.2B | 3.1B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 449.7M | 1.9B | 2.3B | 2.0B | 1.5B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 449.7M | 1.9B | 2.3B | 2.0B | 1.5B |
| Cost and Expenses | 3.4B | 3.5B | 4.2B | 3.3B | 2.7B |
| Operating Income (EBIT) | 287.0M | 166.0M | 129.0M | 1.2B | 1.6B |
| Non-Operating | |||||
| Interest Income | — | 251.0K | 48.0K | 13.0K | 7.0K |
| Interest Expense | 294.0K | 1.3M | 1.4M | 379.0K | 11.0K |
| Net Interest Income | — | (1.1M) | (1.3M) | (366.0K) | (4.0K) |
| Other Non-Op Income/Expense | 18.0K | 916.0K | 107.5M | (27.2M) | 12.6M |
| Non-Operating Income (excl Interest) | — | 15.4M | 124.7M | 29.7M | 25.4M |
| EBT (Pre-Tax Income) | 50.9M | 109.8M | 294.9M | 1.2B | 1.6B |
| Income Tax Expense | 17.3M | 99.2M | 57.0M | 316.5M | 565.8M |
| Bottom Line | |||||
| Net Income | 88.0M | 10.0M | 237.0M | 923.0M | 1.0B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 88.0M | 10.0M | 237.0M | 923.0M | 1.0B |
| Per Share | |||||
| Basic EPS | ¥4 | ¥1 | ¥12 | ¥49 | ¥55 |
| Diluted EPS | ¥4 | ¥1 | ¥12 | ¥48 | ¥53 |
| Revenue Per Share | ¥188 | ¥187 | ¥220 | ¥239 | ¥229 |
| Shares | |||||
| Basic Shares Outstanding | 19.8M | 19.8M | 19.8M | 18.9M | 18.7M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 364.3M | 271.0M | 1.3B | 1.6B |
| D&A | — | 198.3M | 142.0M | 63.9M | 45.4M |
| EBIT | 287.0M | 166.0M | 129.0M | 1.2B | 1.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jan 1, 2026